x

Posted 13 November, 2023

CARGO Therapeutics, Inc. IPO completed

IPO completed detected for ticker Nasdaq:CRGX in a 424B4 filed on 13 November, 2023.


  This is an initial public offering of shares of common stock of CARGO Therapeutics, Inc.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of CARGO Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologous CARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Market Cap
$1.14B
View Company Details
CARGO Therapeutics, Inc. by TradingView